Management of acute respiratory distress syndrome (ARDS) represents one of the greatest challenges in intensive care and despite all efforts mortality remains high. One common phenotype of ARDS is that of a secondary injury to a dysregulated inflammatory host response resulting in increased capillary congestion, interstitial lung edema, atelectasis, pulmonary embolism, muscle wasting, recurring infectious episodes, and multiple organ failure. In cases of hyperinflammation, immunomodulation by extracorporeal cytokine removal such as the CytoSorb hemoadsorption cartridge could conceptually enhance lung recovery during the early course of the disease. The aim of this narrative review is to summarize the currently available data in this field and to provide an overview of pathophysiology and rationale for the use of CytoSorb hemoadsorption in patients with hyperinflammatory ARDS.
VillarJPérez-MéndezLBlancoJ, et al. A universal definition of ARDS: the PaO2/FiO2 ratio under a standard ventilatory setting—a prospective, multicenter validation study. Intensive Care Med2013; 39: 583–592.
2.
SakrYFrançoisBSolé-ViolanJ, et al. Temporal changes in the epidemiology, management, and outcome from acute respiratory distress syndrome in European intensive care units: a comparison of two large cohorts. Crit Care2021; 25: 87.
3.
BellaniGLaffeyJGPhamT, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA2016; 315: 788–800.
4.
ARDS Definition Task Force, RanieriVMRubenfeldGD, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA2012; 307: 2526–2533.
5.
LynnHSunXCasanovaN, et al. Genomic and genetic approaches to deciphering acute respiratory distress syndrome risk and mortality. Antioxid Redox Signal2019; 31: 1027–1052.
6.
FanEDowdyDWColantuoniE, et al. Physical complications in acute lung injury survivors: a two-year longitudinal prospective study. Crit Care Med2014; 42: 849–859.
7.
RuhlAPHuangMColantuoniE, et al. Healthcare resource use and costs in long-term survivors of acute respiratory distress syndrome: a 5-year longitudinal cohort study. Crit Care Med2017; 45: 196–204.
8.
CombesAPeekGJHajageD, et al. ECMO for severe ARDS: systematic review and individual patient data meta-analysis. Intensive Care Med2020; 46: 2048–2057.
9.
GriffithsMJDMcAuleyDFPerkinsGD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res2019; 6: e000420.
10.
StapletonRDWangBMHudsonLD, et al. Causes and timing of death in patients with ARDS. Chest2005; 128: 525–532.
11.
KellumJAKongLFinkMP, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the genetic and inflammatory markers of sepsis (GenIMS) study. Arch Intern Med2007; 167: 1655–1663.
12.
ZhangHHeFLiP, et al. The role of innate immunity in pulmonary infections. Biomed Res Int2021; 2021: 6646071.
13.
MantovaniACassatellaMACostantiniC, et al. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol2011; 11: 519–531.
14.
ReutershanJLeyK. Bench-to-bedside review: acute respiratory distress syndrome - how neutrophils migrate into the lung. Crit Care2004; 8: 453–461.
15.
AbrahamEWunderinkRSilvermanH. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb sepsis Study Group. JAMA1995; 273: 934–941.
16.
FisherCJAgostiJMOpalSM, et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med1996; 334: 1697–1702.
17.
NishSMedzhitovR. Host defense pathways: role of redundancy and compensation in infectious disease phenotypes. Immunity2011; 34: 629–636.
18.
ValentiIE. Characterization of a novel sorbent polymer for the treatment of sepsis. B.S. in Bioengineering, The Pennsylvania State University, 2008. Submitted to the Graduate Faculty of Swanson School of Engineering in partial fulfillment of the requirements for the degree of Master of Science in Bioengineering University of Pittsburgh 2010.
19.
WinchesterJFKellumJARoncoC, et al. Sorbents in acute renal failure and the systemic inflammatory response syndrome. Blood Purif2003; 21: 79–84.
20.
SongMWinchesterJAlbrightRL, et al. Cytokine removal with a novel adsorbent polymer. Blood Purif2004; 22: 428–434.
21.
KellumJASongMVenkataramanR. Hemoadsorption removes tumor necrosis factor, interleukin-6, and interleukin-10, reduces nuclear factor-kappaB DNA binding, and improves short-term survival in lethal endotoxemia. Crit Care Med2004; 32: 801–805.
22.
JansenAWaaldersNJBvan LierDPT, et al. CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo. Crit Care2023; 27: 117.
23.
ScharfCLiebchenUPaalM, et al. Blood purification with a cytokine adsorber for the elimination of myoglobin in critically ill patients with severe rhabdomyolysis. Crit Care2021; 25: 41.
24.
OcskayKTomescuDFaltlhauserA, et al. Hemoadsorption in ‘liver indication’-analysis of 109 patients’ data from the CytoSorb International Registry. J Clin Med2021; 10: 5182.
25.
HassanKKannmacherJWohlmuthP, et al. Cytosorb adsorption during emergency cardiac operations in patients at high risk of bleeding. Ann Thorac Surg2019; 108: 45–51.
26.
HawcharFTomescuDTrägerK, et al. Hemoadsorption in the critically ill—final results of the International CytoSorb Registry. PLoS One2022; 17: e0274315.
27.
SingerMDeutschmanCSSeymourCW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA2016; 315: 801–810.
28.
BrouwerWPDuranSKuijperM, et al. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care2019; 23: 317.
29.
FrieseckeSStecherSSGrossS, et al. Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study. J Artif Organs2017; 20: 252–259.
30.
HawcharFLászlóIÖvegesN, et al. Extracorporeal cytokine adsorption in septic shock: a proof of concept randomized, controlled pilot study. J Crit Care2019; 49: 172–178.
31.
KogelmannKJarczakDSchellerM, et al. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care2017; 21: 74.
32.
DavidSThammKSchmidtBMW, et al. Effect of extracorporeal cytokine removal on vascular barrier function in a septic shock patient. J Intensive Care2017; 5: 12.
33.
PengZYBishopJVWenXY, et al. Modulation of chemokine gradients by apheresis redirects leukocyte trafficking to different compartments during sepsis, studies in a rat model. Crit Care2014; 18: R141.
34.
SchädlerDPauschCHeiseD, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS One2017; 12: e0187015.
35.
HawcharFRaoCAkilA, et al. The potential role of extracorporeal cytokine removal in hemodynamic stabilization in hyperinflammatory shock. Biomedicines2021; 9: 768.
36.
RuggCKloseRHornungR, et al. Hemoadsorption with CytoSorb in septic shock reduces catecholamine requirements and in-hospital mortality: a single-center retrospective ‘genetic’ matched analysis. Biomedicines2020; 8: 539.
37.
KogelmannKSchellerMDrünerM, et al. Use of hemoadsorption in sepsis-associated ECMO-dependent severe ARDS: a case series. J Intensive Care Soc2020; 21: 183–190.
38.
AkilAZiegelerSRehersS, et al. Blood purification therapy in patients with severe COVID-19 requiring veno-venous ECMO therapy: a retrospective study. Int J Artif Organs2022; 45: 615–622.
39.
TzotzosSJFischerBFischerH, et al. Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Crit Care2020; 24: 516.
40.
KonZNSmithDEChangSH, et al. Extracorporeal membrane oxygenation support in severe COVID-19. Ann Thorac Surg2021; 111: 537–543.
41.
CronRQCaricchioRChathamWW. Calming the cytokine storm in COVID-19. Nat Med2021; 27: 1674–1675.
42.
WeiSZhangYZhaiK, et al. CytoSorb in patients with coronavirus disease 2019: a rapid evidence review and meta-analysis. Front Immunol2023; 14: 1067214.
HayangaJWASongTDurhamL, et al. Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry. Crit Care2023; 27(1): 243.
45.
SupadyAWeberERiederM, et al. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial. Lancet Respir Med2021; 9: 755–762.
46.
RampinoTGregoriniMPerottiL, et al. Hemoperfusion with CytoSorb as adjuvant therapy in critically ill patients with SARS-CoV2 pneumonia. Blood Purif2021; 50: 566–571.
47.
AlharthyAFaqihiFMemishZA, et al. Continuous renal replacement therapy with the addition of CytoSorb cartridge in critically ill patients with COVID-19 plus acute kidney injury: a case-series. Artif Organs2021; 45: E101–E112.
48.
PieriMFominskiyENardelliP, et al. CytoSorb purification in critically ill SARS-CoV-2 patients. Int J Artif Organs2022; 45: 216–220.
49.
NassiriAAHakemiMSMiriMM, et al. Blood purification with CytoSorb in critically ill COVID-19 patients: a case series of 26 patients. Artif Organs2021; 45: 1338–1347.
50.
Wunderlich-SperlFKautzkySPickemC, et al. Adjuvant hemoadsorption therapy in patients with severe COVID-19 and related organ failure requiring CRRT or ECMO therapy: a case series. Int J Artif Organs2021; 44: 694–702.
51.
BerlotGTomasiniARoman PognuzE, et al. The combined use of tocilizumab and hemoadsorption in a patient with SARS-COV-2-19-associated pneumonia: a case report. Nephron2020; 144: 459–462.
52.
BerlotGPintacudaSMoroE, et al. Effects of tocilizumab versus hemoadsorption combined with tocilizumab in patients with SARS-CoV-2 pneumonia: preliminary results. Int J Artif Organs2022; 45: 75–80.
53.
AcevedoACZollerMScharfC, et al. CytoSorb® hemoadsorption as a promising tool to handle COVID-19-induced cytokine storm. Case Rep Crit Care2021; 2021: 9937499.
54.
RiederMZahnTBenkC, et al. Cytokine adsorption in a patient with severe coronavirus disease 2019 related acute respiratory distress syndrome requiring extracorporeal membrane oxygenation therapy: a case report. Artif Organs2021; 45: 191–194.
55.
RizviSDanicMSilverM, et al. Cytosorb filter: an adjunct for survival in the COVID-19 patient in cytokine storm? A case report. Heart Lung2021; 50: 44–50.
56.
AlharthyABalhamarAFaqihiF, et al. Rare case of COVID-19 presenting as acute abdomen and sepsis. New Microbes New Infect2020; 38: 100818.
57.
TampeDKorstenPBremerSCB, et al. Kinetics of bilirubin and ammonia elimination during hemadsorption therapy in secondary sclerosing cholangitis following ECMO therapy and severe COVID-19. Biomedicines2021; 9: 1841.
58.
Karabulut KeklikESDalHBozokŞ. Cytokine hemoadsorption in the management of a pregnant woman with COVID-19 pneumonia: case report. SN Compr Clin Med2020; 2: 2376–2380.
59.
AkilAZiegelerSReicheltJ, et al. Combined use of CytoSorb and ECMO in patients with severe pneumogenic sepsis. Thorac Cardiovasc Surg2021; 69: 246–251.
60.
RiederMDuerschmiedDZahnT, et al. Cytokine adsorption in severe acute respiratory failure requiring veno-venous extracorporeal membrane oxygenation. ASAIO J2021; 67: 332–338.
61.
PopescuMDimaSDavidC, et al. Standard renal replacement therapy combined with hemoadsorption in the treatment of critically ill septic patients. Ther Apher Dial2021; 25: 663–670.
62.
BottariGMerliPGuzzoI, et al. Multimodal therapeutic approach of cytokine release syndrome developing in a child given chimeric antigen receptor-modified T cell infusion. Crit Care Explor2020; 2: e0071.
63.
BruengerFKiznerLWeileJ, et al. First successful combination of ECMO with cytokine removal therapy in cardiogenic septic shock: a case report. Int J Artif Organs2015; 38: 113–116.
64.
KelesEFidanKYenicesuI, et al. Successful application of CytoSorb® hemadsorption in an immunocompromised teenager with collapsing glomerulopathy, acute respiratory distress syndrome, and sepsis. Int J Artif Organs2019; 42: 765–769.
65.
LeesNJRosenbergAHurtado-DoceAI, et al. Combination of ECMO and cytokine adsorption therapy for severe sepsis with cardiogenic shock and ARDS due to Panton-Valentine leukocidin-positive Staphylococcus aureus pneumonia and H1N1. J Artif Organs2016; 19: 399–402.
66.
LotherABenkCStaudacherDL, et al. Cytokine adsorption in critically ill patients requiring ECMO support. Front Cardiovasc Med2019; 6: 71.
67.
PaulRJhaBKShettyVK. A case of Viper Snake Bite presenting with gangrene and sepsis associated multiorgan failure, successfully treated with CytoSorb® as an adjunct therapy-a clinical experience. J Evid Based Med Healthc2018; 5: 559–561.
68.
ParikhKPatelHKothariM, et al. A case report to highlight the impact of extracorporeal cytokine elimination therapy in viper snakebite induced septic shock with acute kidney injury. IJMDAT2020; 3: e222.
69.
WiegeleMKrennCG. Cytosorb™ in a patient with Legionella pneumonia-associated rhabdomyolysis: a case report. ASAIO J2015; 61: e14–e16.
70.
KovacevicPTomicBKovacevicT, et al. Use of CytoSorb® as a therapeutic option in a critically ill patient with acute respiratory distress syndrome caused by influenza A (H1N1) pneumonia: a case report. Int J Crit Illn Inj Sci2020; 10: 216–219.
71.
SteurerLMSchlagerGSadeghiK, et al. Hemadsorption as rescue therapy for patients with multisystem organ failure in pediatric intensive care-report of two cases reports and review of the literature. Artif Organs2021; 45: 1582–1593.
72.
Bubenek-TurconiSICorneciDScarlatC, et al. Veno-venous extracorporeal membrane oxygenation, cytokine removal and continuous renal replacement therapy in a severe burn adult patient. Int J Artif Organs2023; 46: 120–125.
73.
SuefkeSSaykFNitschkeM. Hemoadsorption in infection-associated rhabdomyolysis. Ther Apher Dial2016; 20: 531–533.
74.
TacconeFSGardetteMCreteurJ, et al. Hemoadsorption to treat severe iatrogenic intoxication with Patent Blue: a case report. J Med Case Rep2021; 15: 63.
75.
TrägerKSchützCFischerG, et al. Cytokine reduction in the setting of an ARDS-associated inflammatory response with multiple organ failure. Case Rep Crit Care2016; 2016: 9852073.
KogelmannKHübnerTSchwameisF, et al. First evaluation of a new dynamic scoring system intended to support prescription of adjuvant CytoSorb hemoadsorption therapy in patients with septic shock. J Clin Med2021; 10: 2939.
78.
BerlotGTomasiniAZanchiS, et al. The techniques of blood purification in the treatment of sepsis and other hyperinflammatory conditions. J Clin Med2023; 12: 1723.
79.
ScharfCSchroederIPaalM, et al. Can the cytokine adsorber CytoSorb® help to mitigate cytokine storm and reduce mortality in critically ill patients? A propensity score matching analysis. Ann Intensive Care2021; 11: 115.
80.
HeymannMSchorerRPutzuA. Mortality and adverse events of hemoadsorption with CytoSorb® in critically ill patients: a systematic review and meta-analysis of randomized controlled trials. Acta Anaesthesiol Scand2022; 66:1037–1050.
81.
MehtaYPaulRAnsariAS, et al. Extracorporeal blood purification strategies in sepsis and septic shock: an insight into recent advancements. World J Crit Care Med2023; 12: 71–88.
82.
MonardCBianchiNPoliE, et al. Cytokine hemoadsorption with CytoDorb® in post-cardiac arrest syndrome, a pilot randomized controlled trial. Crit Care2023; 27: 36.
83.
HuiWFCheungWLChungFS, et al. The successful application of hemoadsorption for extracorporeal liver support in a child with acute liver failure. Int J Artif Organs2022; 45: 878–882.
84.
DianatySKhodadadiSAlimoghaddamR, et al. Comparison of outcomes and costs of extracorporeal blood purification therapies in critically ill COVID-19 patients. Ther Apher Dial2023; 27: 505–516.
85.
AnkawiGXieYYangB, et al. What have we learned about the use of cytosorb adsorption columns?Blood Purif2019; 48(3): 196–202.
86.
BeckerSLangHVollmer BarbosaC, et al. Efficacy of CytoSorb®: a systematic review and meta-analysis. Crit Care2023;27(1): 215.
87.
SchneiderAGAndréPScheierJ, et al. Pharmacokinetics of anti-infective agents during CytoSorb hemoadsorption. Sci Rep2021; 11(1): 10493.
88.
ScheierJNelsonPJSchneiderA, et al. Mechanistic considerations and pharmacokinetic implications on concomitant drug administration during CytoSorb therapy. Crit Care Explor2022; 4(5): e0688.
